Intellia Therapeutics (NASDAQ: NTLA)
Intellia Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intellia Therapeutics Company Info
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
News & Analysis
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Intellia Tops Revenue Estimates
Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR gene-editing technology.
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
There's nothing bearish at all about what it reported recently.
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
Maybe the Street is a bit too optimistic on this one.
Why Intellia Therapeutics Stock Plummeted by 20% Today
Seemingly encouraging results from the lab were met with some notable skepticism.
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
The Ark Invest portfolio is known for taking aggressive bets.
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
An improbable but serious risk facing the company's investors just got minimized.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.